Most experts would recommend waiting until your disease is stabilized or in remission before starting tirzepatide
Peripheral edema (fluid retention) occurred more frequently with tesamorelin, likely related to GH/IGF-1 effects on sodium and fluid retention
Its dual receptor agonist mechanism has positioned tirzepatide as a major focus in metabolic signaling, glycemic control, endocrine research, and obesity-related pathway investigation
Notably, the reductions observed in these parameters were greater than those seen with semaglutide 1 mg, another GLP-1 receptor agonist, in the SUPRASS-2 trial.Tirzepatide was generally well-tolerated, with a low risk of hypoglycaemia when used without insulin or insulin secretagogues
However, this represents off-label use with limited evidence, and effects are primarily indirect rather than direct hormonal modulation